Literature DB >> 25001613

Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer.

Meiyun Fan1, Aarti Sethuraman, Martin Brown, Wenlin Sun, Lawrence M Pfeffer.   

Abstract

The purpose of this study is to identify metastasis-associated genes/signaling pathways in basal-like breast tumors. Kaplan-Meier analysis of two public meta-datasets and functional classification was used to identify genes/signaling pathways significantly associated with distant metastasis free survival. Integrated analysis of expression correlation and interaction between mRNAs and miRNAs was used to identify miRNAs that potentially regulate the expression of metastasis-associated genes. The novel metastatic suppressive role of miR-17-5p was examined by in vitro and in vivo experiments. Over 4,000 genes previously linked to breast tumor progression were examined, leading to identification of 61 and 69 genes significantly associated with shorter and longer DMFS intervals of patients with basal-like tumors, respectively. Functional annotation linked most of the pro-metastatic genes to epithelial mesenchymal transition (EMT) process and three intertwining EMT-driving pathways (hypoxia, TGFB and Wnt), whereas most of the anti-metastatic genes to interferon signaling pathway. Members of three miRNA families (i.e., miR-17, miR-200 and miR-96) were identified as potential regulators of the pro-metastatic genes. The novel anti-metastatic function of miR-17-5p was confirmed by in vitro and in vivo experiments. We demonstrated that miR-17-5p inhibition in breast cancer cells enhanced expression of multiple pro-metastatic genes, rendered cells metastatic properties, and accelerated lung metastasis from orthotopic xenografts. In contrast, intratumoral administration of miR-17-5p mimic significantly reduced lung metastasis. These results provide evidence supporting that EMT activation and IFN pathway inactivation are markers of metastatic progression of basal-like tumors, and members of miR-17, miR-200, and miR-96 families play a role in suppressing EMT and metastasis. The metastasis-associated genes identified in this study have potential prognostic values and functional implications, thus, can be exploited as therapeutic targets to prevent metastasis of basal-like breast tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25001613      PMCID: PMC4133775          DOI: 10.1007/s10549-014-3040-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  55 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Functional microRNA targets in protein coding sequences.

Authors:  Martin Reczko; Manolis Maragkakis; Panagiotis Alexiou; Ivo Grosse; Artemis G Hatzigeorgiou
Journal:  Bioinformatics       Date:  2012-01-27       Impact factor: 6.937

3.  Molecular signatures database (MSigDB) 3.0.

Authors:  Arthur Liberzon; Aravind Subramanian; Reid Pinchback; Helga Thorvaldsdóttir; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2011-05-05       Impact factor: 6.937

4.  Activation of Wnt11 by transforming growth factor-β drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells.

Authors:  Peng Zhang; Yi Cai; Abdul Soofi; Gregory R Dressler
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

5.  The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.

Authors:  Michael Dews; Jamie L Fox; Stacy Hultine; Prema Sundaram; Wenge Wang; Yingqiu Y Liu; Emma Furth; Gregory H Enders; Wafik El-Deiry; Janell M Schelter; Michele A Cleary; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

6.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

Authors:  Sohrab P Shah; Andrew Roth; Rodrigo Goya; Arusha Oloumi; Gavin Ha; Yongjun Zhao; Gulisa Turashvili; Jiarui Ding; Kane Tse; Gholamreza Haffari; Ali Bashashati; Leah M Prentice; Jaswinder Khattra; Angela Burleigh; Damian Yap; Virginie Bernard; Andrew McPherson; Karey Shumansky; Anamaria Crisan; Ryan Giuliany; Alireza Heravi-Moussavi; Jamie Rosner; Daniel Lai; Inanc Birol; Richard Varhol; Angela Tam; Noreen Dhalla; Thomas Zeng; Kevin Ma; Simon K Chan; Malachi Griffith; Annie Moradian; S-W Grace Cheng; Gregg B Morin; Peter Watson; Karen Gelmon; Stephen Chia; Suet-Feung Chin; Christina Curtis; Oscar M Rueda; Paul D Pharoah; Sambasivarao Damaraju; John Mackey; Kelly Hoon; Timothy Harkins; Vasisht Tadigotla; Mahvash Sigaroudinia; Philippe Gascard; Thea Tlsty; Joseph F Costello; Irmtraud M Meyer; Connie J Eaves; Wyeth W Wasserman; Steven Jones; David Huntsman; Martin Hirst; Carlos Caldas; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2012-04-04       Impact factor: 49.962

Review 7.  Hypoxia-inducible factors and the response to hypoxic stress.

Authors:  Amar J Majmundar; Waihay J Wong; M Celeste Simon
Journal:  Mol Cell       Date:  2010-10-22       Impact factor: 17.970

8.  MicroRNA sequence and expression analysis in breast tumors by deep sequencing.

Authors:  Thalia A Farazi; Hugo M Horlings; Jelle J Ten Hoeve; Aleksandra Mihailovic; Hans Halfwerk; Pavel Morozov; Miguel Brown; Markus Hafner; Fabien Reyal; Marieke van Kouwenhove; Bas Kreike; Daoud Sie; Volker Hovestadt; Lodewyk F A Wessels; Marc J van de Vijver; Thomas Tuschl
Journal:  Cancer Res       Date:  2011-05-17       Impact factor: 12.701

9.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits.

Authors:  Hong Liu; Derek C Radisky; Dun Yang; Ren Xu; Evette S Radisky; Mina J Bissell; J Michael Bishop
Journal:  Nat Cell Biol       Date:  2012-05-13       Impact factor: 28.824

View more
  18 in total

1.  Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21.

Authors:  Ziwei Wang; Feng Ji
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

2.  MicroRNA-20a-5p inhibits epithelial to mesenchymal transition and invasion of endometrial cancer cells by targeting STAT3.

Authors:  Yu Huang; Nian Yang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

Review 3.  Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.

Authors:  Eleni van Schooneveld; Hans Wildiers; Ignace Vergote; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere
Journal:  Breast Cancer Res       Date:  2015-02-18       Impact factor: 6.466

Review 4.  Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?

Authors:  Cristina Sorina Cătană; George A Calin; Ioana Berindan-Neagoe
Journal:  Front Med (Lausanne)       Date:  2015-12-15

5.  Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.

Authors:  Magdalena Zakrzewska; Wojciech Fendler; Krzysztof Zakrzewski; Beata Sikorska; Wiesława Grajkowska; Bożenna Dembowska-Bagińska; Iwona Filipek; Łukasz Stefańczyk; Paweł P Liberski
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

6.  miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.

Authors:  Jie Li; Yuanhui Lai; Jieyi Ma; Yue Liu; Jiong Bi; Longjuan Zhang; Lianzhou Chen; Chen Yao; Weiming Lv; Guangqi Chang; Shenming Wang; Mao Ouyang; Wenjian Wang
Journal:  BMC Cancer       Date:  2017-11-10       Impact factor: 4.430

Review 7.  OncomiR-17-5p: alarm signal in cancer?

Authors:  Madhusudhan Reddy Bobbili; Robert M Mader; Johannes Grillari; Hanna Dellago
Journal:  Oncotarget       Date:  2017-07-18

Review 8.  Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease.

Authors:  Amir Mehrgou; Mansoureh Akouchekian
Journal:  J Res Med Sci       Date:  2017-12-26       Impact factor: 1.852

9.  Down-regulation of traditional oncomiRs in plasma of breast cancer patients.

Authors:  Dana Jurkovicova; Bozena Smolkova; Monika Magyerkova; Zuzana Sestakova; Viera Horvathova Kajabova; Ludovit Kulcsar; Iveta Zmetakova; Lenka Kalinkova; Tomas Krivulcik; Marian Karaba; Juraj Benca; Tatiana Sedlackova; Gabriel Minarik; Zuzana Cierna; Ludovit Danihel; Michal Mego; Miroslav Chovanec; Ivana Fridrichova
Journal:  Oncotarget       Date:  2017-08-24

Review 10.  MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management.

Authors:  Steven C Eastlack; Suresh K Alahari
Journal:  Noncoding RNA       Date:  2015-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.